IS2225B - Fljótvirkandi lyfjablanda - Google Patents

Fljótvirkandi lyfjablanda

Info

Publication number
IS2225B
IS2225B IS6412A IS6412A IS2225B IS 2225 B IS2225 B IS 2225B IS 6412 A IS6412 A IS 6412A IS 6412 A IS6412 A IS 6412A IS 2225 B IS2225 B IS 2225B
Authority
IS
Iceland
Prior art keywords
fast
formulation
acting formulation
given
enterically
Prior art date
Application number
IS6412A
Other languages
English (en)
Other versions
IS6412A (is
Inventor
Gervais Eric
Original Assignee
Duchesnay Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42104724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2225(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc. filed Critical Duchesnay Inc.
Publication of IS6412A publication Critical patent/IS6412A/is
Publication of IS2225B publication Critical patent/IS2225B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lubricants (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Power Steering Mechanism (AREA)
  • Seal Device For Vehicle (AREA)
IS6412A 2000-12-20 2002-06-07 Fljótvirkandi lyfjablanda IS2225B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002350195A CA2350195C (en) 2000-12-20 2000-12-20 Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
PCT/CA2001/000951 WO2003000263A1 (en) 2000-12-20 2001-06-21 Rapid onset formulation
US09/885,051 US6340695B1 (en) 2000-12-20 2001-06-21 Rapid onset formulation

Publications (2)

Publication Number Publication Date
IS6412A IS6412A (is) 2002-12-22
IS2225B true IS2225B (is) 2007-04-15

Family

ID=42104724

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6412A IS2225B (is) 2000-12-20 2002-06-07 Fljótvirkandi lyfjablanda

Country Status (35)

Country Link
US (1) US6340695B1 (is)
EP (1) EP1397133B1 (is)
JP (1) JP4242763B2 (is)
KR (1) KR100527985B1 (is)
CN (1) CN1229112C (is)
AT (1) ATE307582T1 (is)
AU (1) AU2001272243B2 (is)
BE (1) BE1014929A4 (is)
BR (1) BR0107371A (is)
CA (1) CA2350195C (is)
DE (2) DE60114475T2 (is)
DK (2) DK1397133T3 (is)
EG (1) EG24483A (is)
ES (1) ES2251494T3 (is)
FI (1) FI117961B (is)
FR (1) FR2826277B1 (is)
GB (1) GB2383751C (is)
GR (1) GR1004371B (is)
HK (1) HK1052654A1 (is)
HU (1) HU227003B1 (is)
IL (1) IL150349A0 (is)
IS (1) IS2225B (is)
IT (1) ITTO20020524A1 (is)
LU (1) LU90934B1 (is)
MC (1) MC200059A1 (is)
MX (1) MXPA02006037A (is)
MY (1) MY132786A (is)
NL (1) NL1020895C2 (is)
NO (1) NO332190B1 (is)
PL (1) PL204507B1 (is)
SE (1) SE526307C2 (is)
TR (1) TR200201685T1 (is)
UA (1) UA74807C2 (is)
UY (1) UY27352A1 (is)
WO (1) WO2003000263A1 (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US8012506B2 (en) * 2001-04-10 2011-09-06 Pernix Therapeutics, Llc Tannate compositions, methods of making and methods of use
US8257746B2 (en) 2001-04-10 2012-09-04 Pernix Therapeutics, Llc Tannate compositions, methods of making and methods of use
ES2229876B1 (es) * 2001-06-26 2006-03-01 Duchesnay Inc. Formulacion de accion rapida.
CA2392486A1 (en) * 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
US20050004181A1 (en) * 2003-07-03 2005-01-06 Duchesnay Inc. Use of anti-emetic for pre and post operative care
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP2008525313A (ja) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
US20070277530A1 (en) * 2006-05-31 2007-12-06 Constantin Alexandru Dinu Inlet flow conditioner for gas turbine engine fuel nozzle
CN102108059B (zh) * 2010-09-03 2012-05-09 合肥工业大学 一种琥珀酸多西拉敏的合成方法
US8950188B2 (en) 2011-09-09 2015-02-10 General Electric Company Turning guide for combustion fuel nozzle in gas turbine and method to turn fuel flow entering combustion chamber
ES2809713T3 (es) 2012-02-22 2021-03-05 Duchesnay Inc Formulación de doxilamina y piridoxina y/o metabolitos o sales de estas
WO2013123569A1 (en) * 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP2851075B1 (en) 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
MY191347A (en) * 2013-07-22 2022-06-17 Duchesnay Inc Composition for the management of nausea and vomiting
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
WO2016029290A1 (en) * 2014-08-29 2016-03-03 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP3337480A4 (en) 2015-08-17 2019-05-08 Aequus Pharmaceuticals Inc. TRANSDERMAL DELIVERY OF DOXYLAMINE SUCCINATE AND PIRIDOXINE HYDROCHLORIDE
CN105510512B (zh) * 2016-01-25 2018-06-29 南京济群医药科技股份有限公司 一种琥珀酸多西拉敏有关物质的rt-hplc检测方法
SI3628311T1 (sl) * 2018-09-27 2021-04-30 Inibsa Ginecologia, S.A. Proces za pripravo modificiranega sproščanja večenotske oralne dozirne oblike doksilamin sukcinata in piridoksin hidroklorida
CN114099450A (zh) * 2020-08-31 2022-03-01 长春海悦药业股份有限公司 一种比拉斯汀片及其制备方法
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2085641A1 (en) * 1970-04-20 1971-12-31 Investigations Sci Pharm Noramidopyrine doxylamine succinate compsn - antiinflammatories analgesics and antipyretics
US4642231A (en) * 1983-07-20 1987-02-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
ES2096103T3 (es) * 1992-01-13 1997-03-01 Pfizer Preparacion de comprimidos de resistencia incrementada.
CA2139896C (en) * 1995-01-10 2000-03-28 Don B. Mcdonah Use of antinauseant agent for terminally ill humans
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
JP2003509439A (ja) * 1999-09-14 2003-03-11 スミスクライン・ビーチャム・コーポレイション 水性コーティングされたビーズレットの製法
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate

Also Published As

Publication number Publication date
HUP0301950A3 (en) 2005-06-28
PL362763A1 (en) 2004-11-02
CN1447694A (zh) 2003-10-08
HU227003B1 (en) 2010-04-28
EG24483A (en) 2009-08-09
NL1020895A1 (nl) 2002-12-30
SE526307C2 (sv) 2005-08-16
TR200201685T1 (tr) 2003-06-23
IE20020488A1 (en) 2003-04-30
ES2251494T3 (es) 2006-05-01
DE60114475T2 (de) 2006-07-13
GR1004371B (el) 2003-10-23
CN1229112C (zh) 2005-11-30
DE60114475D1 (de) 2005-12-01
EP1397133B1 (en) 2005-10-26
KR100527985B1 (ko) 2005-11-09
SE0202061L (sv) 2003-01-28
ATE307582T1 (de) 2005-11-15
JP2004521146A (ja) 2004-07-15
WO2003000263A1 (en) 2003-01-03
IL150349A0 (en) 2003-12-23
FI117961B (fi) 2007-05-15
AU2001272243B2 (en) 2004-02-05
GB2383751C (en) 2008-08-05
GB2383751A (en) 2003-07-09
GR20020100280A (el) 2003-03-28
ITTO20020524A0 (it) 2002-06-18
PL204507B1 (pl) 2010-01-29
NO20022982L (no) 2002-10-09
HK1052654A1 (en) 2003-09-26
DK1397133T3 (da) 2006-02-27
CA2350195C (en) 2003-06-10
LU90934B1 (fr) 2002-12-23
BR0107371A (pt) 2003-06-10
MC200059A1 (fr) 2003-01-30
GB0213990D0 (en) 2002-07-31
KR20030023612A (ko) 2003-03-19
HUP0301950A2 (hu) 2003-11-28
US6340695B1 (en) 2002-01-22
MY132786A (en) 2007-10-31
FR2826277A1 (fr) 2002-12-27
NO20022982D0 (no) 2002-06-20
UY27352A1 (es) 2002-09-30
UA74807C2 (en) 2006-02-15
DK176018B1 (da) 2005-12-05
EP1397133A1 (en) 2004-03-17
JP4242763B2 (ja) 2009-03-25
IS6412A (is) 2002-12-22
DE10196426T1 (de) 2003-08-21
DK200200947A (da) 2003-01-03
MXPA02006037A (es) 2005-05-12
NL1020895C2 (nl) 2003-03-13
GB2383751B (en) 2005-02-09
FR2826277B1 (fr) 2004-07-02
NO332190B1 (no) 2012-07-23
ITTO20020524A1 (it) 2003-12-18
SE0202061D0 (sv) 2002-07-03
CA2350195A1 (en) 2001-08-11
FI20021708A (fi) 2002-12-22
BE1014929A4 (fr) 2004-06-01
FI20021708A0 (fi) 2002-09-25

Similar Documents

Publication Publication Date Title
IS6412A (is) Fljótvirkandi lyfjablanda
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
AU2001286458A1 (en) Computer program and method for determining the economic impact of long-term care
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
PL346764A1 (en) New oral formulation for 5-ht4
NO994431L (no) Ny formulering
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
NO985807L (no) Transdermale systemer inneholdende 2 aktive ingredienser i separate seksjoner, deres fremstillingsprosess og deres anvendelse som medikament
谷湘潜 et al. A new method to improve the precision of time difference
杨启 et al. Geometric Precision of Datum Line in Shell Plate Expansion Methods
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister
Haight No slowdown in power-gen rental.
UA92310C2 (ru) Композиция, которая включает натеглинид, сахар и микрокристаллическую целлюлозу